Explore 5 years of NHS prescribing data. We’re helping to make prescribing safer and more cost-effective.
We are improving medicine with evidence and data
We are the Evidence-Based Medicine DataLab, at the University of Oxford.
We build innovative, live tools to help make science and healthcare data more impactful in the real world.
We campaign for better, transparent, timely and accessible information in healthcare.
Last week, the Commons Science and Technology Select Committee convened an inquiry following-up their previous clinical trials transparency efforts. The Select Committee has … [Read More...] about Science and Technology Select Committee Follows-Up on Trials Transparency
Get all this information direct to your inbox, monthly: Sign up here. New Paper in BMJ Our newest paper is now out in the BMJ! Here we show … [Read More...] about OpenPrescribing Newsletter October 2019
This is the third instalment in our series of commentaries on using reference ranges to interpret pathology test results. Reference ranges vary between … [Read More...] about OpenPathology: Issues with reference ranges Part 3
This is the second instalment in our series of commentaries on reference ranges used to interpret pathology test results. Here we describe two issues relating to how … [Read More...] about OpenPathology: Issues with Reference Ranges – Part 2
As the OpenPathology project has progressed, we have started to build measures to describe variation between practices, and groups of practices. While comparing rates of … [Read More...] about OpenPathology: Issues with reference ranges – Part 1
In our initial analyses of pathology data from the South West for our OpenPathology.net project, we have noticed subtle but consistent variation in haemoglobin test results … [Read More...] about OpenPathology: Seasonality in Haemoglobin test results
In our initial analyses of pathology data from the South West for our OpenPathology.net project, there is a pronounced (sometimes extreme) increase in high potassium results … [Read More...] about OpenPathology: fake seasonality in potassium results – dangerous and avoidable
Zuclopenthixol is an antipsychotic used for schizophrenia and other psychoses. In the UK, there are two injectable forms of zuclopenthixol: zuclopenthixol acetate : a … [Read More...] about Zuclopenthixol Acetate: a new kind of measure on OpenPrescribing
This week we launched a new measure of seven day prescription for medicines used to treat long-term conditions. There is no current consensus on duration of prescription … [Read More...] about New Measure: Seven Day Prescribing for Long-term Conditions
At the DataLab we regularly collaborate on projects, both small and large, with users who get in touch. For development of this measure we would like to thank the NHS England … [Read More...] about New Measure – Inhalers and the Environment
Get all this information direct to your inbox, monthly: Sign up here. New Feature! Measures linked to Analyse page Following many requests from users, we … [Read More...] about OpenPrescribing Newsletter September 2019
At OpenPathology, we've already found interesting variation in test request rates between practices, but we'd also like to compare whole laboratories. The number of tests … [Read More...] about OpenPathology: getting population sizes right
OpenPathology is our project exploring and feeding back to clinicians on their test requesting rates. Having established that patient counts are subject to some inaccuracy … [Read More...] about Validating pathology data against known shifts in clinical practice
We are excited to reveal some of the data for our new OpenPathology.net project. Similar to our previous project for NHS prescribing data (openprescribing.net/), we are … [Read More...] about Examining variation in test request rates
Get all this information direct to your inbox, monthly: Sign up here. New! Now you can also opt-in for updates about our new project: OpenPathology - read more … [Read More...] about OpenPrescribing Newsletter Summer 2019
This week we have launched a new browser for the NHS Dictionary of Medicines and Devices, better known as dm+d. dm+d is the standard dictionary for the medicines and devices … [Read More...] about NHS dm+d browser – A New Feature on OpenPrescribing
Over the past year we have been increasingly using NHS Dictionary of Medicines and Devices (dm+d). This blog post sets out to describe dm+d for the benefit of the wider … [Read More...] about What is the dm+d? The NHS Dictionary of Medicines and Devices
Earlier this year we noticed a disturbing trend among UK trials registered on the EUCTR. The amount of newly approved and registered trials on the EUCTR dropped drastically … [Read More...] about UK Trials and Brexit – An Update
New low-priority measures approved Yesterday (27 June), NHS England completed its consultation on an additional proposed set of products being considered for a … [Read More...] about OpenPrescribing Newsletter June 2019
Our technical team are busy improving how the engine room of OpenPrescribing. When they've finished we'll get them to write a blog on exactly what they've done. In the … [Read More...] about Additional Functions on Analyse page – multi-level searching and STP/NHS England regions
Update August 2019: Our amazing developers have written all the code necessary to display all prescribing measures and data for all PCNs in England on OpenPrescribing. … [Read More...] about Custom Organisation Groupings: OpenPrescribing Plan for Organisations like Primary Care Networks
This week we have launched a new email alerting service that covers all of NHS England. Many users of OpenPrescribing already receive our monthly newsletter and our innovative … [Read More...] about All England Alerts : A New Feature on OpenPrescribing
Want to receive our updates in your inbox every month? Sign up on the OpenPrescribing homepage. Varied implementation of UTI prescribing guidelines One of our … [Read More...] about OpenPrescribing Newsletter May 2019
Just before Christmas we had a paper published in the Journal of Antimicrobial Chemotherapy. It looked at how GP practices responded to changes to the guidance for … [Read More...] about How can we improve the management of necessary changes in clinical practice?
We recently noticed a very dramatic drop in the number of UK clinical trials post-Brexit on the EU Clinical Trials Register (which would be a catastrophe for British science) … [Read More...] about UK Trials and Brexit
On OpenPrescribing.net we provide data for individual practices and CCGs (and now STPs and regions!) making it easier for everyone to explore NHS prescribing patterns in … [Read More...] about Communicating variation in prescribing – Why We Use Deciles
At the DataLab we value openness and transparency as we believe open discussion of ideas and methods are the key ingredients for high quality data analysis. We think it is … [Read More...] about Openness and Transparency: why is openness and transparency important for good data analysis and how does OpenPrescribing embody it?
In the last year we estimate that price concessions have cost an additional £165 million in unplanned expenditure for Clinical Commissioning Groups (CCGs), and our … [Read More...] about NHS price concessions cost charities and local authorities an additional £5.6 million last year
Today we launched NHS regional and STP dashboards on OpenPrescribing.net, which allow anyone to see NHS prescribing patterns across areas larger than CCGs. You can find these … [Read More...] about NHS Regional and STP Dashboards – A new Feature on OpenPrescribing
It’s been a busy start to the year for the FDAAA TrialsTracker! As the FDAAA TrialsTracker celebrates its 1 year anniversary, we now show over 1000 trials currently overdue to … [Read More...] about FDAAA TrialsTracker: Milestones and Methodology Updates
We are pleased to announce we have secured funding for 10 months from HDRUK to initiate our OpenPathology project, which aims to make an innovative new tool showing … [Read More...] about OpenPathology is go! We are hiring!
New Price Concessions alerts We have introduced a new email alert service, built upon our recently-launched NHS Price Concession calculator, which … [Read More...] about OpenPrescribing February 2019 newsletter
At OpenPrescribing we have a range of prescribing measures that makes it easier for everyone to explore NHS prescribing patterns in England - supporting safer, more efficient … [Read More...] about Building new prescribing measures – we need your help
Ghost Branded Generics are a relatively new category of cost-saving opportunities, caused by prescribers specifying a manufacturer for a generic product, often resulting in a … [Read More...] about Ghost Branded Generics – How to fix it
As you know, here at the DataLab we are working on the RetractoBot project to reduce the number of cited retracted papers. Citations of retracted RCTs are particularly … [Read More...] about Retracted RCTs and clinical guidelines
Today we launched a new feature on OpenPrescribing: an NHS Price Concession email alerts service. This is in addition to our existing calculator that shows cost impact of … [Read More...] about NHS Price Concession Alerts – A new feature on OpenPrescribing
...Identify CCG Cost Savings Opportunities using OpenPrescribing.net Every year in the NHS local teams around the country put together “QIPP Plans”. QIPP stands for … [Read More...] about QIPP Planning: How To…
Nearly all trials of medicinal products conducted in Europe since 2004 are required to post their results directly onto the EU trials register within one year of completion. … [Read More...] about Trial Reporting at NHS Trusts in England
We have recently released two new measures on OpenPrescribing - the prescribing costs of herbal medicines, and the quantity of Freestyle Libre. Herbal … [Read More...] about Two new measures on OpenPrescribing – Herbal medicines and Freestyle Libre
Our EU TrialsTracker has been live for 4 months providing data on who is and isn’t meeting EU trial reporting guidelines. The tracker reached a major milestone last week when … [Read More...] about New Year Updates to the EU TrialsTracker
Before Christmas we wrote about Ghost Branded Generics, a very nerdy story about a problem we uncovered that costs the NHS……...£11.6million a year. Since then we have launched … [Read More...] about Ghost Branded Generics – Positive News!
While investigating the data behind Ghost Branded Generics (more here), we came across something that we didn’t expect. As part of our work in creating the Drug Tariff … [Read More...] about Adventures in time travel with the Drug Tariff
Yesterday, we shared an overview of trial reporting performance for all UK Universities on our EU TrialsTracker and FDAAA TrialsTracker. Today, we are pleased to see this data … [Read More...] about Science and Technology Select Committee Chair Uses EU TrialsTracker Data in Letters to UK Universities
Our EU TrialsTracker has now been live for four months. As of 10 January 2019, we have identified 8,062 trials registered in Europe that are unambiguously due to report … [Read More...] about Trial Reporting at UK Universities
Before Christmas we wrote a nerdy story about Ghost Branded Generics, a problem that costs the NHS £11.6m a year due to prescribers selecting specific manufacturer’s products … [Read More...] about Ghost Branded Generics: A new dashboard on OpenPrescribing
This week we launched a new feature on OpenPrescribing, an NHS Price Concession calculator. We show the cost impact of price concessions for the whole of England here and the … [Read More...] about Price Concessions Calculator – A New Feature on OpenPrescribing
This a very nerdy story about a problem that costs the NHS £11.6m a year. It shows how one small design choice in the software GPs use can have huge ramifications for how we … [Read More...] about Ghost branded generics: Why does the cost of generic atorvastatin vary?
Each year, we estimate there are up to £5m of Out of Pocket Expenses (OOPE) expenses charged to the NHS, added by dispensing contractors to their invoices. Could some of … [Read More...] about Dispensing data shows huge variation in Out of Pocket Expenses
In our third full year of existence we produced even more exciting outputs and continued to grow. We welcomed Lydia Berry, back from maternity leave; Dave Evans, … [Read More...] about 2018 Round-Up
Earlier this week, the Media, Freedom & Information Access Clinic at Yale Law School filed a lawsuit against the heads of the Department of Health and Human Services, the … [Read More...] about New Lawsuit Against US Government Cites FDAAA Tracker
New "do not prescribe" measures on OpenPrescribing.net At OpenPrescribing we pride ourselves on developing our tools in response to the needs of our users. Last week NHS … [Read More...] about OpenPrescribing December 2018 Newsletter
Earlier this week NHS England announced a new "Do Not Prescribe" list for consultation. Within an hour we made graphs showing every GP practice's prescribing of these … [Read More...] about New measures for latest “Do Not Prescribe” list under consultation
The data that drives OpenPrescribing is described briefly in our FAQ. It is supplied by NHSBSA and NHS Digital, and a few other sources. Over the years we have come to … [Read More...] about Limitations of NHS England prescribing data
All England Dashboard – A New Feature on OpenPrescribing.net At OpenPrescribing we pride ourselves on developing our tools in response to the needs of our users. … [Read More...] about OpenPrescribing October 2018 Newsletter
Drug supply issues are an interesting use-case for OpenPrescribing. Here we will talk about a recent example. What is the problem? Last week the Department of Health and … [Read More...] about Phenytoin Supply Disruption Alert
This week we have launched a new page on OpenPrescribing.net, the All England dashboard, that allows anyone to see the quality of prescribing at a national level. For the … [Read More...] about All England Dashboard – A New Feature on OpenPrescribing.net
The EU TrialsTracker, which provides the results reporting status of every trial on the EU Clinical Trials Registry, launched last week alongside a paper in the BMJ. We … [Read More...] about IQWiG Response to the EU TrialsTracker
Earlier this year we launched our FDAAA TrialsTracker, providing a live look at whether individual sponsors and trialists are meeting their responsibility to report the … [Read More...] about The EU TrialsTracker is Live!
Our FDAAA TrialsTracker has been updating each working day since February showing which trials on ClinicalTrials.gov have reported, in compliance with the FDA Amendments Act … [Read More...] about TrialsTracker Project Wins Cochrane-REWARD Prize for Reducing Research Waste
Recently we created antimicrobial stewardship dashboards for every Clinical Commissioning Group and General Practice in England by grouping our measures (see our blog post … [Read More...] about Smoothing seasonality – your feedback needed
Last week, a pharmacist from NHS North Cumbria CCG got our attention by mentioning OpenPrescribing on Twitter. He had just received a letter about a product for treating … [Read More...] about Could North Cumbria save money on haemorrhoid cream?
[this newsletter was sent out on Thurs, Jul 26; sign up to receive the next one at www.openprescribing.net] We do the stats to make your life easy... At OpenPrescribing we … [Read More...] about OpenPrescribing July 2018 newsletter
On February 19, 2018 we launched the FDAAA TrialsTracker, a tool that automatically monitors whether clinical trials are reporting their results to ClinicalTrials.gov in … [Read More...] about FDAAA TrialsTracker Milestones: 6 Months, >1200 trials, $500 Million in Fines
On our OpenPrescribing CCG and practice dashboards you can now filter measures by category to view a small group of related measures together. You can select a category … [Read More...] about New on OpenPrescribing – our measures now have categories!
Updates to OpenPrescribing Thanks largely to our new software developer Dave, we are making some improvements to the site. With the fresh-faced enthusiasm of a new … [Read More...] about OpenPrescribing June 2018 Newsletter
Low-Priority Prescribing Paper Published This week our latest paper was published, which describes the trends and variation in prescribing of medicines determined to be of … [Read More...] about OpenPrescribing May 2018 Newsletter
This is a brief blog about something small and trivial, but also big and important. Recently on the staircase my friend Carl Heneghan came out with a good line about … [Read More...] about “PPPI”: why academics should engage Patients, the Public *and* Professionals
Homeopathy Paper Published Our new paper asks the question: Is use of homeopathy associated with poor prescribing in English primary care? The answer, yes. We found that … [Read More...] about OpenPrescribing April 2018 Newsletter
In February, we posted our first Unreported Trial of the Week here in the Datalab blog highlighting a trial from Columbia University. Since then, that trial has submitted … [Read More...] about Unreported Clinical Trial of the Week Round-Up
Price Concessions – February The Pharmaceutical Services Negotiating Committee (PSNC) have released 3 sets of price concession price lists for February 2018. … [Read More...] about OpenPrescribing March 2018 Newsletter
Our FDAAA TrialsTracker provides a public list of all trials required to report under the FDA Amendments Act of 2007 (FDAAA). We update every weekday with live data showing … [Read More...] about An unreported clinical trial… from the FDA themselves
The Pharmaceutical Services Negotiating Committee (PSNC) have released 3 sets of price concession price lists for February 2018. Once again, the total amount for England for … [Read More...] about Price concessions for February 2018
When you produce online tools from data, you often get useful feedback that helps you improve the outputs. (Send us feedback any time!). Additionally, when you use data, you … [Read More...] about Making the FDAAA TrialsTracker even better than current ClinicalTrials.gov data
Here at the DataLab we are a truly multidisciplinary team: clinicians, academics and software engineers, working together to produce tools, as well as papers. This is … [Read More...] about Welcoming our new DataLab team member, Darren Smyth: a lawyer!
When we launched our FDAAA TrialsTracker we wanted to produce a tool that would improve clinical trial reporting, rather than another repetitive academic journal paper that … [Read More...] about Our FDAAA TrialsTracker is already helping to get new trials reported!
Price Concessions – starting to reduce? The latest price concession information for January has been released by the PSNC (in fact, two sets of data in quick succession). … [Read More...] about OpenPrescribing February 2018 Newsletter
Now that we’ve launched our FDAAA TrialsTracker, we plan on occasionally taking a closer look at some of the trials that go unreported. Our first blog was about a trial … [Read More...] about Why is this trial due to report?
With the launch of our FDAAA TrialsTracker, applicable trials that have failed to report their results on ClinicalTrials.gov are starting to appear. If you go here on our … [Read More...] about Unreported Trial of the Week: NCT01846221
This week, we launched our FDAAA TrialsTracker which gives you a live look at whether individual sponsors and trialists are meeting their responsibility to report the results … [Read More...] about The FDAAA TrialsTracker is Live!
The latest price concession information for January has been released by the PSNC (in fact, two sets of data in quick succession). The PSNC have also stated that they are … [Read More...] about Price Concessions – starting to reduce? UPDATED